These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19464425)

  • 1. Incretin therapies: effects beyond glycemic control.
    Mudaliar S; Henry RR
    Am J Med; 2009 Jun; 122(6 Suppl):S25-36. PubMed ID: 19464425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretin therapies: effects beyond glycemic control.
    Mudaliar S; Henry RR
    Eur J Intern Med; 2009 Jul; 20 Suppl 2():S319-28. PubMed ID: 19580951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unraveling the science of incretin biology.
    Nauck MA
    Eur J Intern Med; 2009 Jul; 20 Suppl 2():S303-8. PubMed ID: 19580949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the science of incretin biology.
    Nauck MA
    Am J Med; 2009 Jun; 122(6 Suppl):S3-S10. PubMed ID: 19464426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
    Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.
    An Z; Prigeon RL; D'Alessio DA
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4702-8. PubMed ID: 24092826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
    Alsalim W; Göransson O; Carr RD; Bizzotto R; Tura A; Pacini G; Mari A; Ahrén B
    Diabetes Obes Metab; 2018 Apr; 20(4):1080-1085. PubMed ID: 29227575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin-based therapy and pancreatic beta cells.
    Chon S; Riveline JP; Blondeau B; Gautier JF
    Diabetes Metab; 2014 Dec; 40(6):411-22. PubMed ID: 25443548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-Based Therapy for Diabetes: What a Cardiologist Needs to Know.
    Waldrop G; Zhong J; Peters M; Rajagopalan S
    J Am Coll Cardiol; 2016 Mar; 67(12):1488-1496. PubMed ID: 27012410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
    Skow MA; Bergmann NC; Knop FK
    Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Achieving glycemic goals with addition of incretin-based therapies to insulin in patients with type 2 diabetes mellitus.
    Tibaldi J
    Am J Med Sci; 2014 Jun; 347(6):491-501. PubMed ID: 24469234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.
    Martin JH; Deacon CF; Gorrell MD; Prins JB
    Intern Med J; 2011 Apr; 41(4):299-307. PubMed ID: 21299778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Cell glutamate signaling: Its role in incretin-induced insulin secretion.
    Yokoi N; Gheni G; Takahashi H; Seino S
    J Diabetes Investig; 2016 Apr; 7 Suppl 1(Suppl 1):38-43. PubMed ID: 27186354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.